Search | Clinical Trials Finder

Conditions: Spondylitis, Ankylosing
Interventions: tocilizumab, Placebo; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 15
States / cities: Huntington Beach, California • Aventura, Florida • Orlando, Florida + 12 more

Conditions: Myasthenia Gravis, Generalized
Interventions: Claseprubart, Placebo, Claseprubart, Placebo; Drug · Combination Product
Lead sponsor: Dianthus Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Pasadena, California • Boca Raton, Florida • Fayetteville, North Carolina + 1 more

Conditions: Parkinson's Disease (PD)
Interventions: TB006, Placebo; Drug
Lead sponsor: TrueBinding, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Aliso Viejo, California • Palo Alto, California • Englewood, Colorado + 11 more

Conditions: Acute Kidney Injury Following Cardiac Surgery
Interventions: TIN816, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years to 100 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Durham, North Carolina

Conditions: Persistent Pulmonary Hypertension, Respiratory Failure
Interventions: Intravenous Sildenafil, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 72 Hours
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more

Conditions: Small Cell Lung Carcinoma
Interventions: Pembrolizumab/Vibostolimab Co-Formulation, Saline placebo, Etoposide, Cisplatin, Atezolizumab, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Mobile, Alabama • Los Angeles, California • Boca Raton, Florida + 7 more

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, Matching Placebo (E2814); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 490 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Healthy Volunteers
Interventions: E2025, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions: Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy; Drug · Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 72
States / cities: Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more

Conditions: Racial Disparities, Blood Pressure, Cardiovascular Risk Factor, Renal Function
Interventions: MitoQ; Dietary Supplement
Lead sponsor: Auburn University; Other
Eligibility: 19 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Kidney Transplantation
Interventions: CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Healthy Volunteers
Interventions: NNC0642-1895, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cutaneous Squamous Cell Carcinoma
Interventions: Cemiplimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 40
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Erlotinib, Onartuzumab (MetMab), Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 56
States / cities: Chandler, Arizona • Hayward, California • Modesto, California + 47 more

Conditions: Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions: Remestemcel-L, Placebo; Biological · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more

Conditions: Colitis, Ulcerative
Interventions: placebo, MultiStem low dose, MultiStem high dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 37
States / cities: San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more

Conditions: Postpartum Depression
Interventions: Placebo, SAGE-547 90 μg/kg/h; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 32
States / cities: Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: Docetaxel, Imatinib mesylate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Fort Myers, Florida • Wichita, Kansas • Williamsville, New York

Conditions: Rheumatoid Arthritis
Interventions: VIB4920, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 18
States / cities: Anniston, Alabama • Sun City, Arizona • Upland, California + 15 more

Conditions: Heart Failure
Interventions: Placebo, Omecamtiv mecarbil; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more

Conditions: Healthy
Interventions: NAV-240, Placebo; Drug
Lead sponsor: Navigator Medicines, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Delayed Graft Function
Interventions: ARGX-117, Placebo; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more

Search by objective public record fields.

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

MSCs in COVID-19 ARDS

A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

Study of NAV-240 in Healthy Volunteers

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function